KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $139000.0.

  • Aquestive Therapeutics' Depreciation & Amortization (CF) fell 1257.86% to $139000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $565000.0, marking a year-over-year decrease of 4556.84%. This contributed to the annual value of $718000.0 for FY2024, which is 4661.71% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Depreciation & Amortization (CF) is $139000.0, which was down 1257.86% from $140000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $755000.0 during Q1 2021, with a 5-year trough of $139000.0 in Q1 2025.
  • For the 5-year period, Aquestive Therapeutics' Depreciation & Amortization (CF) averaged around $412210.5, with its median value being $325000.0 (2023).
  • In the last 5 years, Aquestive Therapeutics' Depreciation & Amortization (CF) skyrocketed by 1763.22% in 2023 and then crashed by 6852.25% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $731000.0 in 2021, then plummeted by 45.69% to $397000.0 in 2022, then rose by 17.63% to $467000.0 in 2023, then crashed by 68.52% to $147000.0 in 2024, then dropped by 5.44% to $139000.0 in 2025.
  • Its last three reported values are $139000.0 in Q3 2025, $140000.0 for Q2 2025, and $139000.0 during Q1 2025.